Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107377 · ClinicalTrials.gov registry record · Phase 2
Phase 2B/3 Double-blinded Placebo-controlled
A Phase 2 study, sponsored by Evofem.
- Completed
- Registry status
- Phase 2
- Development phase
- 860
- Enrollment target
NCT03107377 is a Phase 2 study that has completed, run by Evofem. The registered enrollment target is 860 participants.
The verdict
NCT03107377, a Phase 2 study, has completed, sponsored by Evofem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 860 participants
- Enrollment target
Study Summary
Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection
Interventions
- DRUG Placebo
- DRUG EVO100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2019-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03107377
The ClinicalTrials.gov registry entry for NCT03107377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evofem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03107377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03107377 about?
NCT03107377 is a clinical study titled "Phase 2B/3 Double-blinded Placebo-controlled". Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection
What is the current status of trial NCT03107377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 860 participants. The study started on 2017-11-03. Estimated completion is 2019-08-22.
What interventions are being tested in trial NCT03107377?
The interventions under investigation include: Placebo (DRUG), EVO100 (DRUG).
Who is sponsoring clinical trial NCT03107377?
This trial is sponsored by Evofem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.